73 related articles for article (PubMed ID: 1927119)
1. [The effect of adjuvant combined chemo/immunotherapy on immunological parameters and clinical course in patients with breast carcinoma].
Mallmann P; Krebs D
Zentralbl Gynakol; 1991; 113(12):697-706. PubMed ID: 1927119
[TBL] [Abstract][Full Text] [Related]
2. Investigations on cell-mediated immunity in patients with breast and ovarian carcinomas receiving a combination of chemotherapy and immunotherapy with thymopentin.
Mallmann P; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Jun; 12(5):333-40. PubMed ID: 2232966
[TBL] [Abstract][Full Text] [Related]
3. Effect of tamoxifen and high-dose medroxyprogesterone acetate (MPA) on cell-mediated immune functions in breast cancer patients.
Mallmann P; Dietrich K; Krebs D
Methods Find Exp Clin Pharmacol; 1990 Dec; 12(10):699-706. PubMed ID: 2151629
[TBL] [Abstract][Full Text] [Related]
4. [Effect of tamoxifen on parameters of cell-mediated immunity in postmenopausal patients with breast carcinoma].
Mallmann P; Krebs D
Zentralbl Gynakol; 1991; 113(12):689-96. PubMed ID: 1927118
[TBL] [Abstract][Full Text] [Related]
5. Determination of TNF alpha, interferon alpha, interleukin 2 and reactivity in the leucocyte migration inhibition test in breast cancer patients.
Mallmann P; Diedrich K; Mallmann R; Koenig UD; Krebs D
Anticancer Res; 1991; 11(4):1509-15. PubMed ID: 1746907
[TBL] [Abstract][Full Text] [Related]
6. [The effect of immunotherapy with thymopentin on the parameters of cellular immunity and the clinical course of gynecologic tumor patients].
Mallmann P; Krebs D
Onkologie; 1989 Jun; 12 Suppl 3():15-21. PubMed ID: 2532730
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer.
Meehan KR; Arun B; Gehan EA; Berberian B; Sulica V; Areman EM; Mazumder A; Lippman ME
Bone Marrow Transplant; 1999 Apr; 23(7):667-73. PubMed ID: 10218842
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
Lumsden AJ; Codde JP; Van der Meide PH; Gray BN
Anticancer Res; 1996; 16(3A):1145-54. PubMed ID: 8702226
[TBL] [Abstract][Full Text] [Related]
9. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.
Zaloudik J; Lauerova L; Janakova L; Talac R; Simickova M; Nekulova M; Mikulikova I; Kovarik J; Sheard M
Hepatogastroenterology; 1999; 46(25):220-7. PubMed ID: 10228796
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
11. Relationship of cellular immunity, cytokines and CRP with clinical course in breast cancer patients with endocrine-dependent distant metastases treated with immunotherapy.
Nicolini A; Carpi A; Rossi G
Cancer Lett; 2007 Jun; 251(2):330-8. PubMed ID: 17215077
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
Hong SK; Kwak C; Lee SE
Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2).
Abdel-Wahab M; El-Shennawy F; Agha S; Ragab E; Fathi O; Sultan A; Elghawalby N; Ezzat F
Hepatogastroenterology; 1999 May; 46 Suppl 1():1293-6. PubMed ID: 10429977
[TBL] [Abstract][Full Text] [Related]
14. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
15. Local immunotherapy with interferon-alpha in metastatic pleural and peritoneal effusions: correlation with immunologic parameters.
Stathopoulos GP; Baxevanis CN; Papadopoulos NG; Zarkadis IK; Papacostas P; Michailakis E; Tsiatas ML; Papamichail M
Anticancer Res; 1996; 16(6B):3855-60. PubMed ID: 9042270
[TBL] [Abstract][Full Text] [Related]
16. Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.
Zhang GJ; Adachi I
Anticancer Res; 1999; 19(2B):1427-32. PubMed ID: 10365118
[TBL] [Abstract][Full Text] [Related]
17. Maintenance immunotherapy in metastatic breast cancer.
Recchia F; Sica G; Candeloro G; Necozione S; Bisegna R; Bratta M; Rea S
Oncol Rep; 2008 Nov; 20(5):1173-9. PubMed ID: 18949418
[TBL] [Abstract][Full Text] [Related]
18. Clinical and immunologic effects of T-activin therapy in early stage melanoma patients.
Stanojević-Bakić N; Milosević D; Vucković-Dekić L; Sasić M; Marković L
Neoplasma; 1996; 43(4):245-52. PubMed ID: 8931749
[TBL] [Abstract][Full Text] [Related]
19. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
20. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.
Verra N; de Jong D; Bex A; Batchelor D; Dellemijn T; Sein J; Nooijen W; Meinhardt W; Horenblas S; de Gast G; Vyth-Dreese F
Eur Urol; 2005 Sep; 48(3):527-33. PubMed ID: 16115526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
